Mt. Sinai Spinout Vivaldi Biosciences Nets $23M in Startup Financing
Influenza vaccine developer Vivaldi Biosciences, a spinout of the Mount Sinai School of Medicine in New York, said this week that it has received commitments for $23 million in Series A financing, of which $18.85 million has been funded.
Bay City Capital and NGN Capital co-led the financing, with participation by the New York City Investment Fund and Alexandria Real Estate Equities. The remaining commitments are to be funded subject to achievement of certain milestones, Vivaldi said.